• CMC Strategies With CDMOs: Ensuring CQAs For Oligos And Peptides
    By Published On: November 23, 2024Categories:

    The field of therapeutic development is undergoing rapid transformation, with oligonucleotides and peptides leading the way as promising solutions for addressing a wide array of diseases.

  • Mastering ADC’s Development
    By Published On: November 22, 2024Categories:

    ADC development involves handling highly cytotoxic payloads that demand strict safety measures. Partner with a CDMO equipped with safety certifications(ex: safebridge) and in-depth toxicology expertise to accurately assess exposure risks.

  • Bispecific Antibodies: Mechanism Overview & Development Challenges
    By Published On: November 22, 2024Categories:

    Traditional antibody therapies are designed to target a single antigen. However, many complex diseases are driven by multiple factors, so inhibiting a single target may fail to achieve significant efficacy.

  • Balancing Innovation and Risk Management in R&D
    By Published On: November 22, 2024Categories:

    Biotech, CDMOs, and big pharma must collaborate strategically to balance innovation with risk management in R&D.

  • 8 Key Insights for Finding the Right CDMO
    By Published On: November 22, 2024Categories:

    The digital transformation of CDMO selection is revolutionizing how partnerships are formed. A digitized RFP (Request for Proposal) process can streamline workflows, improve transparency, and ultimately speed up decision-making.

  • Blueprint for Proposal Reviews (RFPs & RFQs): Biotech & CDMO Strategies in the Digital Competitive Era
    By Published On: October 15, 2024Categories:

    The Request for Proposal (RFP) process is not just a formality, but a crucial step in establishing effective collaborations between biotechs and Contract Development and Manufacturing Organizations (CDMOs).

  • Transforming CDMOs through Innovation, Customer-Centricity, and Service Excellence
    By Published On: October 10, 2024Categories:

    CDMOs play a pivotal role in accelerating drug development and manufacturing processes.

  • Biotech Innovation: Guiding points on Fast-to-Clinic / Fast-to-Market Strategies for Biotech & CDMOs
    By Published On: October 10, 2024Categories:

    In the emerging world of biotech innovation, the fast-to-clinic/market strategy has emerged as a critical “mantra” for biotech, investors, and CDMOs.

  • Antibody Drug Conjugates (ADCs) Guiding points on Seamlessly Integrating Development, Manufacturing, Safety, and Supply Chain Excellence
    By Published On: October 10, 2024Categories:

    Antibody-drug conjugates (ADCs) are pioneering biologics that merge antibodies' specificity with small molecules' potency.

  • Driving Biotech Innovation
    By Published On: September 14, 2024Categories:

    This article explores biotech's fast-to-clinic/market strategy, focusing on the role of CDMOs.